- Verona Pharma said a clinical trial of a treatment for respiratory disease did not achieve statistical significance for its primary endpoint.

The three-day Phase 2 clinical trial evaluated the effect of two different doses of nebulized ensifentrine, when used on top of an inhaled long-acting muscarinic antagonist commonly used in the treatment of chronic obstructive pulmonary disease.

The primary endpoint of peak forced expiratory volume after morning dose on day three of treatment was not met with statistical significance, the company said.

The ensifentrine 1.5 mg morning dose, however, improved peak forced expiratory volume by 46 mL, compared to placebo.

Peak forced expiratory volume after evening dose on day three showed statistically significant improvement, compared to placebo, the company added.

Ensifentrine at a 1.5 mg dose produced consistent improvements, compared to placebo, in average forced expiratory volume over 12 hours following the morning dose on days one to three.

However, the improvements were not shown to be statistically significant when adjusted for multiple doses.

'We believe that this short study continues to support our view that ensifentrine may also be of benefit to more severe COPD patients on dual and triple therapy, for whom there are few other treatment options,' chief executive Jan-Anders Karlsson said.

'While we are disappointed that this exploratory Phase 2 study did not achieve statistical significance for its primary endpoint, these data give us clarity on the design, including dose and background therapy, for future long-term studies.'

'We now have the opportunity to also include patients on dual and triple therapy, with the goal of further evaluating ensifentrine's potential to produce sustained bronchodilation and anti-inflammatory effect in this large number of symptomatic COPD patients.'

At 8:21am: [LON:VRP] Verona Pharma PLC share price was -15p at 89p

Story provided by